5
项与 23价肺炎球菌多糖疫苗 (智飞绿竹) 相关的临床试验单中心、开放评价23价肺炎球菌多糖疫苗Ⅲ期临床50岁以上人群免疫持久性的临床试验
单中心、开放评价23价肺炎球菌多糖疫苗Ⅲ期临床50岁以上人群免疫持久性的临床试验
单中心、随机、双盲、组间对照评价23价肺炎球菌多糖疫苗三批一致性及免疫持久性的临床研究
评价规模化生产的三批次23价肺炎球菌多糖疫苗临床免疫效果的一致性以及免疫持久性。
A Randomized, Parallel, Controlled, Exploratory Study: the Efficacy and Safety of Taking Probiotics, Inhaled Antibiotics or Combined Vaccination to Prevent Acute Exacerbation in Subjects With Moderate to Severe COPD and Decolonize Bacteria in Lower Respiratory Tract.
The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD. However, there is no accepted therapy for patients with COPD to remove the colonized bacteria in lower respiratory tract. Therefore, we plan to perform a multi-center, randomized, controlled trial to study the efficacy and safety of oral probiotics, aerosol inhaled amikacin or combined vaccination to decolonize bacteria in lower respiratory tract and prevent acute exacerbation of COPD.
100 项与 23价肺炎球菌多糖疫苗 (智飞绿竹) 相关的临床结果
100 项与 23价肺炎球菌多糖疫苗 (智飞绿竹) 相关的转化医学
100 项与 23价肺炎球菌多糖疫苗 (智飞绿竹) 相关的专利(医药)
100 项与 23价肺炎球菌多糖疫苗 (智飞绿竹) 相关的药物交易